eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | cystic fibrosis |
| Symptom | |infection |
| Sentences | 124 |
| PubMedID- 22540844 | During chronic lung infection of patients with cystic fibrosis, pseudomonas aeruginosa can survive for long periods of time under the challenging selective pressure imposed by the immune system and antibiotic treatment as a result of its biofilm mode of growth and adaptive evolution mediated by genetic variation. |
| PubMedID- 24031589 | Pseudomonas aeruginosa is a common cause of chronic pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 26442462 | Background: mycobacterium abscessus infection in patients with cystic fibrosis (cf) can result in accelerated clinical decline and the potential for direct or indirect transmission between patients has been recently demonstrated. |
| PubMedID- 23137712 | Treatment of lung infection in patients with cystic fibrosis: current and future strategies. |
| PubMedID- 22970300 | Possession of certain genes and expression of their gene products may predispose different strains of h. influenzae to successful chronic infection in patients with cystic fibrosis or copd. |
| PubMedID- 25034564 | Chronic airway infection in adults with cystic fibrosis (cf) is polymicrobial and the impact of intravenous antibiotics on the bacterial community composition is poorly understood. |
| PubMedID- 24439251 | Dermatitidis triggers antibody production and may cause significant airway infection in patients with cystic fibrosis. |
| PubMedID- 25596784 | cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. |
| PubMedID- 22551926 | Burkholderia cepacia complex (bcc) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 26268854 | The opportunistic pathogen pseudomonas aeruginosa causes chronic lung infection in patients with cystic fibrosis. |
| PubMedID- 20941680 | Conclusion: ecmo is a another treatment option for serious ards in infection-related worsening of pulmonary cystic fibrosis. |
| PubMedID- 22084956 | Economic burden of pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 25221853 | Purpose of review: newer 'innovative' formulations of antibiotics for pseudomonas aeruginosa lung infection in patients with cystic fibrosis include colistimethate sodium and tobramycin in the form of dry powders for inhalation (dpis). |
| PubMedID- 21883670 | Initial pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. |
| PubMedID- 22216191 | It is also an emerging infection in patients with cystic fibrosis . |
| PubMedID- 24194436 | Tobramycin inhalation powder: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 24489509 | Treatment of pseudomonas and staphylococcus bronchopulmonary infection in patients with cystic fibrosis. |
| PubMedID- 19996339 | Treatment of early pseudomonas aeruginosa infection in patients with cystic fibrosis: the elite trial. |
| PubMedID- 22230402 | Aeruginosa causes chronic lung infection in individuals with cystic fibrosis and nosocomial pneumonia resulting in significant morbidity and mortality. |
| PubMedID- 21297072 | Aeruginosa during infection of patients with cystic fibrosis, and provide in vivo evidence for a link between pyocyanin production and patient morbidity. |
| PubMedID- 25590621 | These results highlight a dynamic bacterial-host interaction between an opportunistic pathogen that causes chronic infections in the lungs of individuals with cystic fibrosis, an infection site known to be rich in neutrophil dna and neutrophil extracellular traps . |
| PubMedID- 21833328 | P. aeruginosa is also the most common cause of chronic airway infection in individuals with cystic fibrosis (cf). |
| PubMedID- 21114855 | For example, in this study, the target proteins were from p. aeruginosa, a gram negative bacterial opportunistic pathogen that causes serious lung infections in people with cystic fibrosis, and several tm proteins involved in infection were found to be expressed at sufficient levels for further study. |
| PubMedID- 23030647 | During the last decades it has emerged as a cause of chronic pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 21977035 | There have been a number of studies demonstrating p. aeruginosa cross-infection between patients with cystic fibrosis . |
| PubMedID- 24730990 | Bacteria of the burkholderia cepacia complex: epidemiology and diagnosis of infection in patients with cystic fibrosis. |
| PubMedID- 22563440 | This is the first prospective randomized controlled clinical trial to explore whether treatment of chronic a. fumigatus airway infection in patients with cystic fibrosis provides clinical benefits. |
| PubMedID- 24324555 | However, p. aeruginosa is a significant cause of chronic infection and morbidity in patients with cystic fibrosis and chronic obstructive pulmonary disease, ventilator-associated pneumonia, and immunocompromised patients. |
| PubMedID- 21625534 | Therefore, in this study we have explored whether pleiotropic subcellular stressors and effects related to misfolded protein processing will mitigate barriers to infection using models of cystic fibrosis (cf). |
| PubMedID- 21039067 | We present the case of a cystic fibrosis-young man diagnosed with hcv infection during lt assessment who was treated with pegi/r. |
| PubMedID- 22330747 | Caveolin 2, which localizes to the golgi complex but redistributes to plasma membrane, caveolae and rafts when co-expressed with caveolin 1, is a potential key molecule related to the pseudomonas infection causing pneumonia in patients with cystic fibrosis and other immunocompromising conditions . |
| PubMedID- 25742660 | Mycobacterium abscessus specific t-cells were detected in the blood of cystic fibrosis patients with confirmed chronic infection and a subgroup of patients without evidence of mycobacterium abscessus infection. |
| PubMedID- 21703477 | Inhaled antibiotics have been used for more than 30 years to treat bronchial colonization or infection, especially in patients with cystic fibrosis and chronic bronchial infection with pseudomonas. |
| PubMedID- 23701325 | Why is pseudomonas aeruginosa a common cause of infection in individuals with cystic fibrosis. |
| PubMedID- 24766052 | Chronic pulmonary pseudomonal infection in patients with cystic fibrosis: a model for early phase symbiotic evolution. |
| PubMedID- 23152277 | Selection criteria: randomized controlled trials of antibiotic therapy based on biofilm antimicrobial susceptibility testing compared to antibiotic therapy based on conventional antimicrobial susceptibility testing in the treatment of pseudomonas aeruginosa pulmonary infection in individuals with cystic fibrosis. |
| PubMedID- 25191584 | (150)hydrogen cyanide is released by the pathogen,pseudomonas aeruginosa, and the detection of highconcentrations of hydrogen cyanide in breath may be used for the early detectionof bacterial infection of children with cystic fibrosisshestivska et al. |
| PubMedID- 24232573 | Samples from wound infections and lungs of patients with cystic fibrosis often contains both p. aeruginosa and s. aureus, underscoring the clinical importance of co-infection by these two bacteria.24,25 it has been shown that interaction of p. aeruginosa and gram-positive bacteria including s. aureus can lead to increased virulence in p. aeruginosa.26 there is little information available about the interaction between these two bacterial pathogens and the importance of this interaction with regards to the severity and outcome of infection. |
| PubMedID- 26534255 | Adherence to inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis: a systematic literature review. |
| PubMedID- 24522146 | Tobramycin powder for inhalation (tobi podhaler or tip) is approved for the treatment of pseudomonas aeruginosa airway infection in patients with cystic fibrosis (cf). |
| PubMedID- 25417708 | Levofloxacin inhalation solution for the treatment of chronic pseudomonas aeruginosa infection among patients with cystic fibrosis. |
| PubMedID- 22869452 | Mycobacterium tuberculosis infection in patients with cystic fibrosis (cf) is rare. |
| PubMedID- 23737089 | Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis. |
| PubMedID- 20137079 | Feasibility study to inform the design of a randomised controlled trial to eradicate pseudomonas aeruginosa infection in individuals with cystic fibrosis. |
| PubMedID- 20504347 | Other reports suggest that bacterial infection associated with cystic fibrosis induces metaplastic bone replacement, as well as the destruction and elimination of the bronchial cartilage 9. |
| PubMedID- 21511763 | P. aeruginosa infections associated with cystic fibrosis are resistant to current therapies, and molecules inhibiting toxin production or signals controlling their production should be able to reduce infection and aid in the clearance of this pathogen. |
| PubMedID- 20927769 | Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis. |
| PubMedID- 19887136 | Vaccination against pseudomonas aeruginosa is a desirable, yet challenging strategy for prevention of airway infection in patients with cystic fibrosis. |
| PubMedID- 25624972 | Lung disease in cystic fibrosis results from chronic airway infection and inflammation leading to progressive bronchiectasis and respiratory failure . |
| PubMedID- 24464974 | Introduction: aerosolized tobramycin is a standard of care for chronic pseudomonas aeruginosa (pa) infection in patients with cystic fibrosis (cf). |